Pneumococcal Conjugate Vaccine for stem cell transplant recipients 2022-2024 (2024-2025, 2025-2026)

The Ministry of Social Affairs and Health (hereinafter ”STM”) and Finnish Institute for Health and Welfare (hereinafter "THL" or “Customer” ) request your tender for Pneumococcal conjugate Vaccine for stem cell transplant recipients belonging to the National Vaccination Programme in Finland. The contract period is about two years 2022-2024. The procurement contains two options to extend the contract for the periods 2024-2025 and 2025-2026. Customer reserves the right to increase or decrease the ordered numbers of doses by up to 20%. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition.

The purpose of STM and the Customer is to procure Pneumococcal conjugate Vaccine for stem cell transplant recipients required for the National Vaccination Programme in Finland. The tendered vaccine must be suitable for both children and adults. More information about National Vaccination Programme and vaccinations can be found on the website of the National Institute for Health and Welfare: https://thl.fi/en/web/infectious-diseases-and-vaccinations/vaccines-a-to-z/pneumococcal-vaccines/pneumococcal-conjugate-vaccine-pcv The Customer will implement the procurement on behalf of STM. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority".